Skip to main content

Table 1 Characteristics of the discovery and the validation cohorts

From: A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy

  C3 (discovery, n = 864) C5 (validation, n = 242)
Characteristic n % n %
Sex
 Male 579 67.0 165 68.2
 Female 285 33.0 77 31.8
T
 1 476 55.1 124 51.2
 2 122 14.1 21 8.7
 3 251 29.1 92 38
 4 13 1.5 4 1.7
 NA 2 0.2 1 0.4
N
 0 322 37.3 173 71.5
 1/2 46 5.3 26 10.7
 X 495 57.3 40 16.5
 NA 1 0.1 3 1.2
M
 0 537 62.2 170 70.2
 1 82 9.5 38 15.7
 X 209 24.2 33 13.6
 NA 36 4.2 1 0.4
Histology
 ccRCC 512 59.3 134 55.4
 pRCC 287 33.2 86 35.5
 chRCC 65 7.5 16 6.6
 mixed 0 0.0 6 2.5
Overall survival
 Alive 648 75.0 161 66.5
 Deceased 216 25.0 81 33.5
CSS
 Censored 714 82.6 188 77.7
 Events 135 15.6 54 22.3
 NA 15 1.7 0 0.0
Follow-up, years
 Median 3.0 4.8
 Range 0 to 16.2 0 to 21.2
 NA 2 0.2 0 0.0
Age, years
 Median 60 64
 Range 17 to 90 25 to 90
 NA 3 0.3 0 0.0
Tumor size, cm
 Median 5.1 5.8
 Range 1 to 25 1.3 to 17.7
 NA 105 12.2 2 0.8
  1. NA Not available, CSS Cancer-specific survival